For its second fiscal quarter (ending June 30), Sarepta Therapeutics Inc (NASDAQ: SRPT) has reported E.P.S. of $0.07 compared to $-0.27 a year ago. This performance was $-0.40 short of the consensus estimate of $0.47. E.P.S. were $0.48 for the latest four quarters through June 30 versus $-10.29 for the same period a year ago.
Recent Price Action
On 8/7/24, Sarepta Therapeutics Inc (NASDAQ: SRPT) stock declined modestly by -2.0%, closing at $140.06. However, trading volume in this decline was below average at 77% of normal. The stock has declined -2.1% during the last week but has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
SRPT is expected to be a major Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
Sarepta Therapeutics has a current Value Trend Rating of A (Highest Rating). The Value Trend Rating reflects highly consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Sarepta Therapeutics has a very high Power Rating of 86 and a very high Appreciation Score of 88, triggering the Highest Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of A. This review will be completed in the next several days.
Be the first to comment